世界のアジソン病治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Addison’s Disease Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0091 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、アジソン病治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬品、ホルモン療法、手術）、用途別市場規模（病院、在宅医療、専門クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・アジソン病治療の市場動向 ・企業の競争状況、市場シェア ・アジソン病治療の種類別市場規模（薬品、ホルモン療法、手術） ・アジソン病治療の用途別市場規模（病院、在宅医療、専門クリニック、その他） ・アジソン病治療の北米市場規模2016-2027（アメリカ、カナダ） ・アジソン病治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・アジソン病治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・アジソン病治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・アジソン病治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Bristol-Myers Squibb、Merck、Novartis、Pfizer、Takeda Pharmaceutical、Bio-Techne、GlaxoSmithKline、Lupin Pharmaceuticals、Abbott、Amgen、Bayer、Biogen、Eli Lilly and Company、Boehringer Ingelheim International、Diurnal、Switzer Life Science、Recipharm） ・結論

Addison’s Disease is to point to because adrenal cortex hormone secretion is insufficient a kind of systemic disease that causes.Those caused by adrenal gland diseases themselves are called primary adrenocortical hypoxia, and those caused by hypothalamus and/or pituitary diseases are called secondary adrenocortical hypoxia.The main manifestations are fatigue, loss of appetite, nausea, vomiting, low blood pressure, etc., severe cases may appear shock, hyponatrium, hypoglycemia and other adrenal crisis performance.Primary person still has systemic skin mucous membrane pigmentation.Lifelong alternative therapy, that is, supplementation of physiological quantities of adrenal corticosteroids.

Market Analysis and Insights: Global Addison’s Disease Therapeutics Market
The global Addison’s Disease Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Addison’s Disease Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Addison’s Disease Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Addison’s Disease Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Addison’s Disease Therapeutics market.

Global Addison’s Disease Therapeutics Scope and Market Size
Addison’s Disease Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Addison’s Disease Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Medication
Hormonal Therapy
Surgery

Segment by Application
Hospitals
Homecare
Specialty Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bristol-Myers Squibb
Merck
Novartis
Pfizer
Takeda Pharmaceutical
Bio-Techne
GlaxoSmithKline
Lupin Pharmaceuticals
Abbott
Pfizer
Takeda Pharmaceutical
Biogen
Eli Lilly and Company
Boehringer Ingelheim International
Diurnal

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Addison’s Disease Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Medication
1.2.3 Hormonal Therapy
1.2.4 Surgery
1.3 Market by Application
1.3.1 Global Addison’s Disease Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Homecare
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Addison’s Disease Therapeutics Market Perspective (2016-2027)
2.2 Addison’s Disease Therapeutics Growth Trends by Regions
2.2.1 Addison’s Disease Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Addison’s Disease Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Addison’s Disease Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Addison’s Disease Therapeutics Industry Dynamic
2.3.1 Addison’s Disease Therapeutics Market Trends
2.3.2 Addison’s Disease Therapeutics Market Drivers
2.3.3 Addison’s Disease Therapeutics Market Challenges
2.3.4 Addison’s Disease Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Addison’s Disease Therapeutics Players by Revenue
3.1.1 Global Top Addison’s Disease Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Addison’s Disease Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Addison’s Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Addison’s Disease Therapeutics Revenue
3.4 Global Addison’s Disease Therapeutics Market Concentration Ratio
3.4.1 Global Addison’s Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Addison’s Disease Therapeutics Revenue in 2020
3.5 Addison’s Disease Therapeutics Key Players Head office and Area Served
3.6 Key Players Addison’s Disease Therapeutics Product Solution and Service
3.7 Date of Enter into Addison’s Disease Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Addison’s Disease Therapeutics Breakdown Data by Type
4.1 Global Addison’s Disease Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Addison’s Disease Therapeutics Forecasted Market Size by Type (2022-2027)

5 Addison’s Disease Therapeutics Breakdown Data by Application
5.1 Global Addison’s Disease Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Addison’s Disease Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Addison’s Disease Therapeutics Market Size (2016-2027)
6.2 North America Addison’s Disease Therapeutics Market Size by Type
6.2.1 North America Addison’s Disease Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Addison’s Disease Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Addison’s Disease Therapeutics Market Size by Type (2016-2027)
6.3 North America Addison’s Disease Therapeutics Market Size by Application
6.3.1 North America Addison’s Disease Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Addison’s Disease Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Addison’s Disease Therapeutics Market Size by Application (2016-2027)
6.4 North America Addison’s Disease Therapeutics Market Size by Country
6.4.1 North America Addison’s Disease Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Addison’s Disease Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Addison’s Disease Therapeutics Market Size (2016-2027)
7.2 Europe Addison’s Disease Therapeutics Market Size by Type
7.2.1 Europe Addison’s Disease Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Addison’s Disease Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Addison’s Disease Therapeutics Market Size by Type (2016-2027)
7.3 Europe Addison’s Disease Therapeutics Market Size by Application
7.3.1 Europe Addison’s Disease Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Addison’s Disease Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Addison’s Disease Therapeutics Market Size by Application (2016-2027)
7.4 Europe Addison’s Disease Therapeutics Market Size by Country
7.4.1 Europe Addison’s Disease Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Addison’s Disease Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Addison’s Disease Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Addison’s Disease Therapeutics Market Size by Type
8.2.1 Asia-Pacific Addison’s Disease Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Addison’s Disease Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Addison’s Disease Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Addison’s Disease Therapeutics Market Size by Application
8.3.1 Asia-Pacific Addison’s Disease Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Addison’s Disease Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Addison’s Disease Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Addison’s Disease Therapeutics Market Size by Region
8.4.1 Asia-Pacific Addison’s Disease Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Addison’s Disease Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Addison’s Disease Therapeutics Market Size (2016-2027)
9.2 Latin America Addison’s Disease Therapeutics Market Size by Type
9.2.1 Latin America Addison’s Disease Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Addison’s Disease Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Addison’s Disease Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Addison’s Disease Therapeutics Market Size by Application
9.3.1 Latin America Addison’s Disease Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Addison’s Disease Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Addison’s Disease Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Addison’s Disease Therapeutics Market Size by Country
9.4.1 Latin America Addison’s Disease Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Addison’s Disease Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Addison’s Disease Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Addison’s Disease Therapeutics Market Size by Type
10.2.1 Middle East & Africa Addison’s Disease Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Addison’s Disease Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Addison’s Disease Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Addison’s Disease Therapeutics Market Size by Application
10.3.1 Middle East & Africa Addison’s Disease Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Addison’s Disease Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Addison’s Disease Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Addison’s Disease Therapeutics Market Size by Country
10.4.1 Middle East & Africa Addison’s Disease Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Addison’s Disease Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Addison’s Disease Therapeutics Introduction
11.1.4 Bristol-Myers Squibb Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Addison’s Disease Therapeutics Introduction
11.2.4 Merck Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.2.5 Merck Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Addison’s Disease Therapeutics Introduction
11.3.4 Novartis Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.3.5 Novartis Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Addison’s Disease Therapeutics Introduction
11.4.4 Pfizer Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 Takeda Pharmaceutical
11.5.1 Takeda Pharmaceutical Company Details
11.5.2 Takeda Pharmaceutical Business Overview
11.5.3 Takeda Pharmaceutical Addison’s Disease Therapeutics Introduction
11.5.4 Takeda Pharmaceutical Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.5.5 Takeda Pharmaceutical Recent Development
11.6 Bio-Techne
11.6.1 Bio-Techne Company Details
11.6.2 Bio-Techne Business Overview
11.6.3 Bio-Techne Addison’s Disease Therapeutics Introduction
11.6.4 Bio-Techne Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.6.5 Bio-Techne Recent Development
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Details
11.7.2 GlaxoSmithKline Business Overview
11.7.3 GlaxoSmithKline Addison’s Disease Therapeutics Introduction
11.7.4 GlaxoSmithKline Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.7.5 GlaxoSmithKline Recent Development
11.8 Lupin Pharmaceuticals
11.8.1 Lupin Pharmaceuticals Company Details
11.8.2 Lupin Pharmaceuticals Business Overview
11.8.3 Lupin Pharmaceuticals Addison’s Disease Therapeutics Introduction
11.8.4 Lupin Pharmaceuticals Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.8.5 Lupin Pharmaceuticals Recent Development
11.9 Abbott
11.9.1 Abbott Company Details
11.9.2 Abbott Business Overview
11.9.3 Abbott Addison’s Disease Therapeutics Introduction
11.9.4 Abbott Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.9.5 Abbott Recent Development
11.10 Amgen
11.10.1 Amgen Company Details
11.10.2 Amgen Business Overview
11.10.3 Amgen Addison’s Disease Therapeutics Introduction
11.10.4 Amgen Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.10.5 Amgen Recent Development
11.11 Bayer
11.11.1 Bayer Company Details
11.11.2 Bayer Business Overview
11.11.3 Bayer Addison’s Disease Therapeutics Introduction
11.11.4 Bayer Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.11.5 Bayer Recent Development
11.12 Biogen
11.12.1 Biogen Company Details
11.12.2 Biogen Business Overview
11.12.3 Biogen Addison’s Disease Therapeutics Introduction
11.12.4 Biogen Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.12.5 Biogen Recent Development
11.13 Eli Lilly and Company
11.13.1 Eli Lilly and Company Company Details
11.13.2 Eli Lilly and Company Business Overview
11.13.3 Eli Lilly and Company Addison’s Disease Therapeutics Introduction
11.13.4 Eli Lilly and Company Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.13.5 Eli Lilly and Company Recent Development
11.14 Boehringer Ingelheim International
11.14.1 Boehringer Ingelheim International Company Details
11.14.2 Boehringer Ingelheim International Business Overview
11.14.3 Boehringer Ingelheim International Addison’s Disease Therapeutics Introduction
11.14.4 Boehringer Ingelheim International Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.14.5 Boehringer Ingelheim International Recent Development
11.15 Diurnal
11.15.1 Diurnal Company Details
11.15.2 Diurnal Business Overview
11.15.3 Diurnal Addison’s Disease Therapeutics Introduction
11.15.4 Diurnal Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.15.5 Diurnal Recent Development
11.16 Switzer Life Science
11.16.1 Switzer Life Science Company Details
11.16.2 Switzer Life Science Business Overview
11.16.3 Switzer Life Science Addison’s Disease Therapeutics Introduction
11.16.4 Switzer Life Science Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.16.5 Switzer Life Science Recent Development
11.17 Recipharm
11.17.1 Recipharm Company Details
11.17.2 Recipharm Business Overview
11.17.3 Recipharm Addison’s Disease Therapeutics Introduction
11.17.4 Recipharm Revenue in Addison’s Disease Therapeutics Business (2016-2021)
11.17.5 Recipharm Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Addison’s Disease Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Medication
Table 3. Key Players of Hormonal Therapy
Table 4. Key Players of Surgery
Table 5. Global Addison’s Disease Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Addison’s Disease Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Addison’s Disease Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Addison’s Disease Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Addison’s Disease Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Addison’s Disease Therapeutics Market Share by Regions (2022-2027)
Table 11. Addison’s Disease Therapeutics Market Trends
Table 12. Addison’s Disease Therapeutics Market Drivers
Table 13. Addison’s Disease Therapeutics Market Challenges
Table 14. Addison’s Disease Therapeutics Market Restraints
Table 15. Global Addison’s Disease Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Addison’s Disease Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Addison’s Disease Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Addison’s Disease Therapeutics as of 2020)
Table 18. Ranking of Global Top Addison’s Disease Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Addison’s Disease Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Addison’s Disease Therapeutics Product Solution and Service
Table 22. Date of Enter into Addison’s Disease Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Addison’s Disease Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Addison’s Disease Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Addison’s Disease Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Addison’s Disease Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Addison’s Disease Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Addison’s Disease Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Addison’s Disease Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Addison’s Disease Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Addison’s Disease Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Addison’s Disease Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Addison’s Disease Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Addison’s Disease Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Addison’s Disease Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Addison’s Disease Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Addison’s Disease Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Addison’s Disease Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Addison’s Disease Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Addison’s Disease Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Addison’s Disease Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Addison’s Disease Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Addison’s Disease Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Addison’s Disease Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Addison’s Disease Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Addison’s Disease Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Addison’s Disease Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Addison’s Disease Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Addison’s Disease Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Addison’s Disease Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Addison’s Disease Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Addison’s Disease Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Addison’s Disease Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Addison’s Disease Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Addison’s Disease Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Addison’s Disease Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Addison’s Disease Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Addison’s Disease Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Addison’s Disease Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Addison’s Disease Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. Bristol-Myers Squibb Company Details
Table 63. Bristol-Myers Squibb Business Overview
Table 64. Bristol-Myers Squibb Addison’s Disease Therapeutics Product
Table 65. Bristol-Myers Squibb Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 66. Bristol-Myers Squibb Recent Development
Table 67. Merck Company Details
Table 68. Merck Business Overview
Table 69. Merck Addison’s Disease Therapeutics Product
Table 70. Merck Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Merck Recent Development
Table 72. Novartis Company Details
Table 73. Novartis Business Overview
Table 74. Novartis Addison’s Disease Therapeutics Product
Table 75. Novartis Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Novartis Recent Development
Table 77. Pfizer Company Details
Table 78. Pfizer Business Overview
Table 79. Pfizer Addison’s Disease Therapeutics Product
Table 80. Pfizer Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. Takeda Pharmaceutical Company Details
Table 83. Takeda Pharmaceutical Business Overview
Table 84. Takeda Pharmaceutical Addison’s Disease Therapeutics Product
Table 85. Takeda Pharmaceutical Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 86. Takeda Pharmaceutical Recent Development
Table 87. Bio-Techne Company Details
Table 88. Bio-Techne Business Overview
Table 89. Bio-Techne Addison’s Disease Therapeutics Product
Table 90. Bio-Techne Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 91. Bio-Techne Recent Development
Table 92. GlaxoSmithKline Company Details
Table 93. GlaxoSmithKline Business Overview
Table 94. GlaxoSmithKline Addison’s Disease Therapeutics Product
Table 95. GlaxoSmithKline Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 96. GlaxoSmithKline Recent Development
Table 97. Lupin Pharmaceuticals Company Details
Table 98. Lupin Pharmaceuticals Business Overview
Table 99. Lupin Pharmaceuticals Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Lupin Pharmaceuticals Recent Development
Table 101. Abbott Company Details
Table 102. Abbott Business Overview
Table 103. Abbott Addison’s Disease Therapeutics Product
Table 104. Abbott Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 105. Abbott Recent Development
Table 106. Amgen Company Details
Table 107. Amgen Business Overview
Table 108. Amgen Addison’s Disease Therapeutics Product
Table 109. Amgen Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 110. Amgen Recent Development
Table 111. Bayer Company Details
Table 112. Bayer Business Overview
Table 113. Bayer Addison’s Disease Therapeutics Product
Table 114. Bayer Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 115. Bayer Recent Development
Table 116. Biogen Company Details
Table 117. Biogen Business Overview
Table 118. Biogen Addison’s Disease Therapeutics Product
Table 119. Biogen Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 120. Biogen Recent Development
Table 121. Eli Lilly and Company Company Details
Table 122. Eli Lilly and Company Business Overview
Table 123. Eli Lilly and Company Addison’s Disease Therapeutics Product
Table 124. Eli Lilly and Company Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 125. Eli Lilly and Company Recent Development
Table 126. Boehringer Ingelheim International Company Details
Table 127. Boehringer Ingelheim International Business Overview
Table 128. Boehringer Ingelheim International Addison’s Disease Therapeutics Product
Table 129. Boehringer Ingelheim International Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 130. Boehringer Ingelheim International Recent Development
Table 131. Diurnal Company Details
Table 132. Diurnal Business Overview
Table 133. Diurnal Addison’s Disease Therapeutics Product
Table 134. Diurnal Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 135. Diurnal Recent Development
Table 136. Switzer Life Science Company Details
Table 137. Switzer Life Science Business Overview
Table 138. Switzer Life Science Addison’s Disease Therapeutics Product
Table 139. Switzer Life Science Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 140. Switzer Life Science Recent Development
Table 141. Recipharm Company Details
Table 142. Recipharm Business Overview
Table 143. Recipharm Addison’s Disease Therapeutics Product
Table 144. Recipharm Revenue in Addison’s Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 145. Recipharm Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Addison’s Disease Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Medication Features
Figure 3. Hormonal Therapy Features
Figure 4. Surgery Features
Figure 5. Global Addison’s Disease Therapeutics Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Homecare Case Studies
Figure 8. Specialty Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Addison’s Disease Therapeutics Report Years Considered
Figure 11. Global Addison’s Disease Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Addison’s Disease Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Addison’s Disease Therapeutics Market Share by Regions: 2020 VS 2027
Figure 14. Global Addison’s Disease Therapeutics Market Share by Regions (2022-2027)
Figure 15. Global Addison’s Disease Therapeutics Market Share by Players in 2020
Figure 16. Global Top Addison’s Disease Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Addison’s Disease Therapeutics as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Addison’s Disease Therapeutics Revenue in 2020
Figure 18. Global Addison’s Disease Therapeutics Revenue Market Share by Type (2016-2021)
Figure 19. Global Addison’s Disease Therapeutics Revenue Market Share by Type (2022-2027)
Figure 20. North America Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Addison’s Disease Therapeutics Market Share by Type (2016-2027)
Figure 22. North America Addison’s Disease Therapeutics Market Share by Application (2016-2027)
Figure 23. North America Addison’s Disease Therapeutics Market Share by Country (2016-2027)
Figure 24. United States Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Addison’s Disease Therapeutics Market Share by Type (2016-2027)
Figure 28. Europe Addison’s Disease Therapeutics Market Share by Application (2016-2027)
Figure 29. Europe Addison’s Disease Therapeutics Market Share by Country (2016-2027)
Figure 30. Germany Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Addison’s Disease Therapeutics Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Addison’s Disease Therapeutics Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Addison’s Disease Therapeutics Market Share by Region (2016-2027)
Figure 40. China Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Addison’s Disease Therapeutics Market Share by Type (2016-2027)
Figure 48. Latin America Addison’s Disease Therapeutics Market Share by Application (2016-2027)
Figure 49. Latin America Addison’s Disease Therapeutics Market Share by Country (2016-2027)
Figure 50. Mexico Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Addison’s Disease Therapeutics Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Addison’s Disease Therapeutics Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Addison’s Disease Therapeutics Market Share by Country (2016-2027)
Figure 56. Turkey Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Addison’s Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Bristol-Myers Squibb Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 60. Merck Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 61. Novartis Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 62. Pfizer Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 63. Takeda Pharmaceutical Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 64. Bio-Techne Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 65. GlaxoSmithKline Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 66. Lupin Pharmaceuticals Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 67. Abbott Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 68. Amgen Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 69. Bayer Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 70. Biogen Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 71. Eli Lilly and Company Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 72. Boehringer Ingelheim International Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 73. Diurnal Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 74. Switzer Life Science Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 75. Recipharm Revenue Growth Rate in Addison’s Disease Therapeutics Business (2016-2021)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed

---